Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.71 |
| ▸ | MAPT | P10636 | 7/20 | 0.71 |
| ▸ | MEN1 | O00255 | 7/20 | 0.71 |
| ▸ | LMNA | P02545 | 5/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.71 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | CASP7 | P55210 | 1/20 | 0.60 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16546406 | 1.00 | KMT2A (0.71) | KMT2AMAPTMEN1LMNATDP1 | |
| Dantrolene SCHEMBL40893 | 0.83 | MAPT (1.00) | KMT2AMAPTMEN1LMNATDP1 | |
| Dantrolene SCHEMBL56848 | 0.83 | MAPT (1.00) | KMT2AMAPTMEN1LMNATDP1 | |
| SCHEMBL13005953 | 0.83 | MAPT (0.61) | KMT2AMAPTMEN1LMNATDP1 | |
| Dantrolene SCHEMBL2903719 | 0.82 | MAPT (0.98) | KMT2AMAPTMEN1LMNATDP1 | |
| Dantrolene SCHEMBL946529 | 0.82 | MAPT (0.98) | KMT2AMAPTMEN1LMNATDP1 | |
| Dantrolene SCHEMBL29510578 | 0.82 | MAPT (0.98) | KMT2AMAPTMEN1LMNATDP1 | |
| Dantrolene SCHEMBL2903716 | 0.82 | MAPT (0.98) | KMT2AMAPTMEN1LMNATDP1 | |
| Dantrolene SCHEMBL4223149 | 0.82 | MAPT (0.98) | KMT2AMAPTMEN1LMNATDP1 | |
| Dantrolene SCHEMBL979318 | 0.82 | MAPT (0.98) | KMT2AMAPTMEN1LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975284-B2 | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents | US WORLDMEDS LLC (US) | 2015-03-10 | — | — | US | claimed |
| US-20110015243-A2 | CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPUTIC AGENTS | US WORLDMEDS, LLC (US) | 2011-01-20 | — | — | US | claimed |
| US-20090093531-A1 | Co-Solvent Compositions and Methods for Improved Delivery of Dantrolene Therapeutic Agents | US WORLDMEDS LLC | 2009-04-09 | — | — | US | claimed |
| US-8975284-B2 | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents | US WORLDMEDS LLC (US) | 2015-03-10 | — | — | US | disclosed |
| EP-2583670-A1 | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents | US Worldmeds LLC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20110160261-A2 | CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS | US WORLDMEDS, LLC (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110015243-A2 | CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPUTIC AGENTS | US WORLDMEDS, LLC (US) | 2011-01-20 | — | — | US | disclosed |
| US-20090093531-A1 | Co-Solvent Compositions and Methods for Improved Delivery of Dantrolene Therapeutic Agents | US WORLDMEDS LLC | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093531-A1 | Co-Solvent Compositions and Methods for Improved Delivery of Dantrolene Therapeutic Agents | TERT, TBCA, TTR | KMT2A 1079/4885MAPT 677/4885MEN1 2329/4885 |
| US-20110160261-A2 | CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS | TERT, TBCA, TTR | KMT2A 1079/4885MAPT 677/4885MEN1 2329/4885 |
| US-20110015243-A2 | CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPUTIC AGENTS | TERT, TTR, TTPA | KMT2A 1043/4885MAPT 806/4885MEN1 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.